Showing results (471-480 of 785) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|December 3, 2020
Multi-stakeholder consensus on a target product profile for an HIV cureSharon R Lewin, Timothy Attoye, Cathy Bansbach, et al.
The Lancet. HIV|December 14, 2020
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platformKrishnan Bhaskaran, Christopher T Rentsch, Brian MacKenna, et al.
The Lancet. HIV|March 4, 2021
Prioritising pleasure and correcting misinformation in the era of U=USarah K Calabrese, Kenneth H Mayer, Julia L Marcus
The Lancet. HIV|December 2, 2021
Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countriesWin Min Han, Matthew G Law, Matthias Egger, et al.
The Lancet. HIV|November 4, 2022
Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2: a prespecified secondary outcomes analysis of the HPTN 071 (PopART) community-randomised trialEthan Wilson, Deborah Donnell, Timothy Skalland, et al.
The Lancet. HIV|October 14, 2022
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panelMaurine D Miner, Mark Hatherill, Vidya Mave, et al.
The Lancet. HIV|September 30, 2022
Differences in healthy longevity by HIV status and viral load among older South African adults: an observational cohort modelling studyCollin F Payne, Brian Houle, Chido Chinogurei, et al.
The Lancet. HIV|October 6, 2022
So many harms, so little benefit: a global review of the history and harms of HIV criminalisationJoanne Csete, Richard Elliott, Edwin J Bernard
The Lancet. HIV|October 3, 2022
Disseminating complex primary outcome results from a community-randomised trial to Zambian communities: lessons learned using a community dialogue approach in the HPTN 071 (PopART) trialMusonda Simwinga, Rhoda Ndubani, Albertus Schaap, et al.
The Lancet. HIV|February 21, 2022
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trialHylke Waalewijn, Man K Chan, Pauline D J Bollen, et al.
Pageof 79